|
1 Indications And Usage Lartruvo™ Is Indicated, In Combination With Doxorubicin, For The Treatment Of Adult Patients With Soft Tissue Sarcoma (sts) With A Histologic Subtype For Which An Anthracycline-Containing Regimen Is Appropriate And Which Is Not Amenable To Curative Treatment With Radiotherapy Or Surgery. This Indication Is Approved Under Accelerated Approval [see Clinical Studies ( 14 )] . Continued Approval For This Indication May Be Contingent Upon Verification And Description Of Clinical Benefit In The Confirmatory Trial. Lartruvo™ Is A Platelet-Derived Growth Factor Receptor Alpha (pdgfr-Α) Blocking Antibody Indicated, In Combination With Doxorubicin, For The Treatment Of Adult Patients With Soft Tissue Sarcoma (sts) With A Histologic Subtype For Which An Anthracycline-Containing Regimen Is Appropriate And Which Is Not Amenable To Curative Treatment With Radiotherapy Or Surgery. ( 1 ) This Indication Is Approved Under Accelerated Approval. Continued Approval For This Indication May Be Contingent Upon Verification And Description Of Clinical Benefit In The Confirmatory Trial. ( 14 )
|